Conference Presentations

PLENARY SESSIONS

  • THIRD PLENARY SESSION: EVOLUTION OF VALUE: PERSPECTIVES FROM BOTH SIDES OF THE ATLANTIC

    Presentation

    Jérôme Wittwer
    PhD, Professor, Economics, Bordeaux University, Bordeaux, France
  • THIRD PLENARY SESSION: EVOLUTION OF VALUE: PERSPECTIVES FROM BOTH SIDES OF THE ATLANTIC
  • THIRD PLENARY SESSION: EVOLUTION OF VALUE: PERSPECTIVES FROM BOTH SIDES OF THE ATLANTIC

    Presentation

    Mandy Ryan
    PhD, MSc, Director of the Health Economics Research Unit, Institute of Applied Health Sciences, College of Life Sciences and Medicine, University of Aberdeen, Aberdeen, UK
  • SECOND PLENARY SESSION: APPRAISING THE APPRAISERS: WHAT IS THE FUTURE OF HEALTH TECHNOLOGY ASSESSMENT IN EUROPE?

    Presentation

    Zoe Garrett
    MRes, MPhil, Technical Adviser, National Institute for Health and Care Excellence (NICE), Centre for Health Technology Evaluation, London, UK
  • SECOND PLENARY SESSION: APPRAISING THE APPRAISERS: WHAT IS THE FUTURE OF HEALTH TECHNOLOGY ASSESSMENT IN EUROPE?

    Presentation

    Nicola Allen
    PhD, Senior Consultant, Global Pricing and Product Strategy, Precision Xtract, London, UK
  • SECOND PLENARY SESSION: APPRAISING THE APPRAISERS: WHAT IS THE FUTURE OF HEALTH TECHNOLOGY ASSESSMENT IN EUROPE?

    Presentation

    Susan Guthrie
    PhD, MSci, Research Leader, Rand Europe, Cambridge, UK
  • FIRST PLENARY SESSION: WHERE IS THE VALUE IN VALUE-BASED HEALTH CARE?

    Presentation

    Luke Slawomirski
    Health Economist & Policy Analyst, Directorate for Employment, Labour and Social Affairs, Organisation for Economic Co-operation and Development (OECD), Paris, France
  • FIRST PLENARY SESSION: WHERE IS THE VALUE IN VALUE-BASED HEALTH CARE?

    Presentation

    Jason Arora
    BMBCh, MPH, Director, Value-Based Healthcare, Medtronic, London, UK
  • FIRST PLENARY SESSION: WHERE IS THE VALUE IN VALUE-BASED HEALTH CARE?

    Presentation

    Bettina Ryll
    MD, PhD, Founder, Melanoma Patient Network Europe and Chair, Patient Advocates Working Group, European Society for Medical Oncology (ESMO), Uppsala, Sweden
  • FIRST PLENARY SESSION: WHERE IS THE VALUE IN VALUE-BASED HEALTH CARE?

    Presentation

    Peter Naredi
    Professor of Surgery & Head, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg and President, European CanCer Organization (ECCO), Brussels, Belgium
  • FIRST PLENARY SESSION: WHERE IS THE VALUE IN VALUE-BASED HEALTH CARE?

    Presentation

    Maarten J. IJzerman
    PhD, Professor & Chair, University of Twente and MIRA Institute for Biomedical Technology & Technical Medicine, Department of Health Technology & Services Research, Enschede, The Netherlands

ISSUE PANEL PRESENTATIONS

  • IP1 : PRAGMATIC CLINICAL TRIALS TO ESTIMATE TREATMENT EFFECTS: ARE THEY WORTH THE EFFORT?

    Presentation

    Rita M. Kristy
    MS, Director - Statistics, Clinical and Outcomes Sciences, Astellas Pharma Global Development, Northbrook, USA
    Keith R. Abrams
    PhD, CStat, Professor of Medical Statistics, NIHR Senior Investigator Emeritus & Head, Biostatistics Research Group, University of Leicester, Department of Health Sciences, Leicester, UK
    Christoph Gerlinger
    PD, Senior Director, Bayer AG, Development, Pharmaceuticals, Berlin, Germany
  • IP10 : DOES VALUATION OF INNOVATION IN APPRAISAL OF NEW TECHNOLOGIES PROVIDE APPROPRIATE INCENTIVES FOR MANUFACTURERS AND ACCESS FOR PATIENTS?

    Presentation

    Jens Grueger
    PhD, Vice President, Head of Global Health Economics & Pricing, F. Hoffmann-La Roche, Global Health Economics & Pricing, Basel, Switzerland
  • IP10 : DOES VALUATION OF INNOVATION IN APPRAISAL OF NEW TECHNOLOGIES PROVIDE APPROPRIATE INCENTIVES FOR MANUFACTURERS AND ACCESS FOR PATIENTS?

    Presentation

    Karl Claxton
    PhD, Professor of Economics, University of York, Centre for Health Economics and Department of Economics, Heslington, York, UK
  • IP10 : DOES VALUATION OF INNOVATION IN APPRAISAL OF NEW TECHNOLOGIES PROVIDE APPROPRIATE INCENTIVES FOR MANUFACTURERS AND ACCESS FOR PATIENTS?
  • IP11 : DETERMINING VALUE IN HEALTH TECHNOLOGY ASSESSMENT CONSISTENT WITH SOCIETAL AIMS: PURSUE NEW OPTIONS?

    Presentation

    Michael Schlander
    MD, PhD, MBA, Chairman & Scientific Director, University of Heidelberg, Institute for Innovation & Valuation in Health Care, Wiesbaden, Germany
  • IP11 : DETERMINING VALUE IN HEALTH TECHNOLOGY ASSESSMENT CONSISTENT WITH SOCIETAL AIMS: PURSUE NEW OPTIONS?

    Presentation

    Alistair Mcguire
    PhD, Professor of Health Economics, London School of Economics, London, UK
  • IP11 : DETERMINING VALUE IN HEALTH TECHNOLOGY ASSESSMENT CONSISTENT WITH SOCIETAL AIMS: PURSUE NEW OPTIONS?

    Presentation

    John Brazier
    PhD, MSc, Professor of Health Economics and Dean, University of Sheffield, School of Health and Related Research (ScHARR), Sheffield, UK
  • IP12 : WHAT SHOULD PATIENT-CENTERED CARE MEAN IN THE WELFARE STATES OF EUROPE? THE UNITED KINGDOM AND GERMANY CANNOT BOTH BE RIGHT

    Presentation

    F. Reed Johnson
    PhD, Senior Research Scholar, Duke University, Duke Clinical Research Institute, Durham, USA
    Axel C. Mühlbacher
    PhD, MBA, Professor of Health Economics and Health Care Management, Hochschule Neubrandenburg, Institute Health Economics and Health Care Management, IGM, Neubrandenburg, Germany
  • IP14 : PATIENT-CENTERED DECISION MAKING: HOW DO YOU GENERATE RELEVANT PATIENT-REPORTED OUTCOMES EVIDENCE FOR CHRONIC DISEASE MANAGEMENT AND MARKET-ACCESS DECISION MAKING?

    Presentation

    Katharine Barnard
    PhD CPsychol AFBPsS, Visiting Professor, Bournemouth University, Poole, UK
    Francois Meyer
    PhD, Advisor to the President, Haute Autorité de Santé (HAS), International Affairs, Saint-Denis, France
    Simon O'Neill
    REG.N., Director of Health Intelligence and Professional Liaison, Diabetes UK, London, UK
  • IP14 : PATIENT-CENTERED DECISION MAKING: HOW DO YOU GENERATE RELEVANT PATIENT-REPORTED OUTCOMES EVIDENCE FOR CHRONIC DISEASE MANAGEMENT AND MARKET-ACCESS DECISION MAKING?

    Presentation

    Katharine Barnard
    PhD CPsychol AFBPsS, Visiting Professor, Bournemouth University, Poole, UK
  • IP14 : PATIENT-CENTERED DECISION MAKING: HOW DO YOU GENERATE RELEVANT PATIENT-REPORTED OUTCOMES EVIDENCE FOR CHRONIC DISEASE MANAGEMENT AND MARKET-ACCESS DECISION MAKING?

    Presentation

    Finn Børlum Kristensen
    MD, PhD, Professor, Health Services Research & Health Technology Assessment, Danish Health and Medicines Authority, University of Southern Denmark and Director, EUnetHTA Secretariat, Copenhagen, Denmark
  • IP15 : A MODEST PROPOSAL: CAN WE EASE THE BURDEN OF MYRIAD MEASURES WITH A MINIMUM DATA SET THAT ACTUALLY MATTERS TO PATIENTS?

    Presentation

    Charles D. Petrie
    PhD, Vice President, Outcomes and Evidence, Pfizer, Inc., Global Health & Value, Groton, USA
  • IP15 : A MODEST PROPOSAL: CAN WE EASE THE BURDEN OF MYRIAD MEASURES WITH A MINIMUM DATA SET THAT ACTUALLY MATTERS TO PATIENTS?

    Presentation

    Roman Casciano
    MS, Executive Vice President and Head, Value and Access, LASER Analytica, New York, USA
  • IP15 : A MODEST PROPOSAL: CAN WE EASE THE BURDEN OF MYRIAD MEASURES WITH A MINIMUM DATA SET THAT ACTUALLY MATTERS TO PATIENTS?
  • IP16 : MANAGED ENTRY SCHEMES FOR MEDICAL DEVICES: GREAT OPPORTUNITY OR MAJOR CHALLENGE?

    Presentation

    Richard Charter
    MSc, Head of Market Access & Pricing Diabetes Care Europe, Becton Dickinson AG, Allschwil, Switzerland
  • IP16 : MANAGED ENTRY SCHEMES FOR MEDICAL DEVICES: GREAT OPPORTUNITY OR MAJOR CHALLENGE?

    Presentation

    Aleksandra Torbica
    PhD, Professor, Bocconi University, Milano, Italy
  • IP16 : MANAGED ENTRY SCHEMES FOR MEDICAL DEVICES: GREAT OPPORTUNITY OR MAJOR CHALLENGE?

    Presentation

    Michael Drummond
    MCom, DPhil, Professor of Health Economics, University of York, Centre for Health Economics, Heslington, York, UK
  • IP18 : HOW WILL HEALTH CARE SYSTEMS HANDLE FUTURE ONCOLOGY COMBINATION PRODUCT LAUNCHES?

    Presentation

    Bettina Ryll
    MD, PhD, Founder, Melanoma Patient Network Europe and Chair, Patient Advocates Working Group, European Society for Medical Oncology (ESMO), Uppsala, Sweden
  • IP19 : CAN THE PATIENT VOICE BE BETTER INCORPORATED INTO THE NICE PROCESS?

    Presentation

    Jennifer Lee
    MBA, HEMAR & Advocacy Director, Janssen UK, Health Economics, Market Access, Reimbursement, & Advocacy, High Wycombe, UK
    Eric Low
    NA, Former CEO of Myeloma UK, N/A, East Lothian, UK
    Heidi Livingstone
    BA, Project Manager, Patient and Public Involvement Manager, NICE, London, UK
    Richard Jackson
    PGCE, NPQH, Patient Expert (Currently a Primary School Headteacher), NA (Hillview Primary School), NA, UK
  • IP9 : SHOULD RARE ONCOLOGY TREATMENTS BE CONSIDERED TRUE ORPHANS?

    Presentation

    Elangovan Gajraj
    MSc, Senior Technical Adviser, National Institute for Health and Care Excellence, Scientific Advice, London, UK
    Annabel Griffiths
    PhD, Consultant, Costello Medical Consulting Ltd, Cambridge, UK
    Ivana Cattaneo
    MBA, Public Affairs Director, Novartis Farma S.p.A, Novartis Oncology Europe, Origgio (VA), Italy
    Pan Pantziarka
    PhD, Project Co-ordinator, Anti-Cancer Fund, Strombeek-Bever, Belgium

WORKSHOP PRESENTATIONS

  • W1 : WHERE DO WE NEED GOOD RESEARCH PRACTICE GUIDANCE IN HEALTH TECHNOLOGY ASSESSMENT?

    Presentation

    Mirjana Huić
    MD, PhD, Assistant Director, Agency for Quality and Accreditation in Health Care and Social Welfare, Department for Development, Research and Health Technology Assessment, Zagreb, Croatia
    Sophie Werkö
    PhD, MSc, Project Director, Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU), Stockholm, Sweden
  • W10 : EQ-5D: IS NICE READY FOR THE NEXT LEVEL?

    Presentation

    Rosemary Lovett
    PhD, Senior Scientific Adviser, National Institute for Health and Care Excellence (NICE), Science Policy and Research Programme, London, UK
  • W10 : EQ-5D: IS NICE READY FOR THE NEXT LEVEL?

    Presentation

    Allan Wailoo
    MA, MSc, PhD, Professor of Health Economics, University of Sheffield, School of Health and Related Research, Sheffield, UK
  • W17 : COMPARING, CONTRASTING, AND VALIDATING HEALTH ECONOMIC DECISION MODELS: EXPERIENCES FROM THE LATEST MT. HOOD CHALLENGE IN DIABETES AND LESSONS FOR OTHER DISEASE AREAS

    Presentation

    Mark Lamotte
    MD, Cardiologist, Senior principal, QuintilesIMS, RWES, Zaventem, Belgium
    Michael Willis
    PhD, Research Director, The Swedish Institute for Health Economics, Lund, Sweden
    Talitha Feenstra
    PhD, Senior Researcher / Assistant Professor, RIVM /UMCG, Bilthoven, The Netherlands
  • W18 : FROM ONE TO MANY: WHEN GROUPS – NOT CZARS – MAKE DECISIONS

    Presentation

    Guruprasad Madhavan
    PhD, Senior Program Officer, National Academies of Science, Engineering, and Medicine, Health and Medicine, Washington, USA
  • W2 : PATIENT POWERED REGISTRIES: USEFUL FOR HEALTH TECHNOLOGY ASSESSMENT OR NOT?

    Presentation

    Elisabeth M. Oehrlein
    BA, PhD Candidate, University of Maryland, School of Pharmacy, Pharmaceutical Health Services Research, Baltimore, USA
    Robert N. McBurney
    PhD, Chief Executive Officer, Accelerated Cure Project for Multiple Sclerosis, Waltham, USA
    Gurmit Sandhu
    B Pharm (Hons), MBA, MPH, Patient Engagement Specialist, Gurmit Sandhu Consulting GmbH, Basel, Switzerland
    Chantal Guilhaume
    PharmD, Scientific Project Manager, EUnetHTA JA3; Direction de l'Evaluation Médicale, Economique et de Santé Publique (DEMESP), Haute Autorité de Santé, Saint-Denis La Plaine, France
  • W21 : COMPARING TREATMENTS BY COMBINING DATA FROM VARIOUS RANDOMIZED AND OBSERVATIONAL STUDIES: INTRODUCTION TO CONCEPT, METHODS, AND APPLICATION

    Presentation

    Farhan Mughal
    MRPharmS, MSc, Associate Director, Celgene Ltd, Health Economics and Outcomes Research, Uxbridge, UK
    Susanne Schmitz
    PhD, Postdoctoral Fellow, Luxembourg Institute of Health, Department of Population Health / Health Economics and Evidence Synthesis Research Unit, Strassen, Luxembourg
    Viktor Chirikov
    PhD, Scientist, Pharmerit International, Bethesda, USA
  • W22 : NEGOTIATING PRICE AND DATA IN AN ERA OF CONDITIONAL APPROVAL: “STICK” OR “TWIST”?

    Presentation

    Daniel Gladwell
    MSc, Principal Consultant, BresMed Health Solutions LTD, Sheffield, UK
    Alan Brennan
    PhD, Professor of Health Economics and Decision Modelling, University of Sheffield, School of Health and Related Research (ScHARR), Sheffield, UK
    Warren Cowell
    MSc, National Market Access Policy Lead, Janssen Inc., High Wycombe, UK
    Ash Bullement
    BSc, Health Economist, BresMed Health Solutions, Sheffield, UK
  • W23 : IMPROVING PERFORMANCE OF ALGORITHMS TO POWER UNMET NEED AND EFFECTIVENESS IN HEALTH ECONOMICS AND OUTCOMES RESEARCH USING ELECTRONIC HEALTH RECORDS AND HEALTH CARE CLAIMS DATA SOURCES

    Presentation

    Schiffon L Wong
    MPH, Franchise Head Neurology, Global Evidence & Value Development, EMD Serono, Inc., Global Research & Development, Billerica, USA
    Aaron WC Kamauu
    MD, MS, MPH, CEO, Anolinx LLC, Salt Lake City, USA
    Hoa Van Le
    MD, PhD, Senior Consultant, PAREXEL INTERNATIONAL, DURHAM, USA
    Monica Gaines Kobayashi
    PhD, MBMA, Consultant, PAREXEL International, Real World Evidence & Data Analytics, Durham, USA
  • W24 : POPULATION-ADJUSTED TREATMENT COMPARISONS IN HEALTH TECHNOLOGY ASSESSMENT: AN OVERVIEW OF APPROACHES AND PERSPECTIVES

    Presentation

    David M. Phillippo
    MSc, BSc, Research Associate in Evidence Synthesis, University of Bristol, School of Social and Community Medicine, Bristol, UK
  • W24 : POPULATION-ADJUSTED TREATMENT COMPARISONS IN HEALTH TECHNOLOGY ASSESSMENT: AN OVERVIEW OF APPROACHES AND PERSPECTIVES

    Presentation

    Mark Belger
    BSc, Principal Research Scientist, Eli Lilly, GSS, Ascot, UK
  • W24 : POPULATION-ADJUSTED TREATMENT COMPARISONS IN HEALTH TECHNOLOGY ASSESSMENT: AN OVERVIEW OF APPROACHES AND PERSPECTIVES

    Presentation

    Nicky J. Welton
    PhD, MSc, Reader in Evidence Synthesis, University of Bristol, School of Social and Community Medicine, Bristol, UK
  • W5 : SUSTAINABLE FUNDING AND FAIR PRICING FOR ORPHAN DRUGS: WHAT ARE THE SOLUTIONS?

    Presentation

    Martina Garau
    Senior Economist, Office of Health Economics, London, UK
  • W5 : SUSTAINABLE FUNDING AND FAIR PRICING FOR ORPHAN DRUGS: WHAT ARE THE SOLUTIONS?
  • W5 : SUSTAINABLE FUNDING AND FAIR PRICING FOR ORPHAN DRUGS: WHAT ARE THE SOLUTIONS?
  • W6 : GENERATING REAL-WORLD EVIDENCE FOR REAL-WORLD DECISIONS: APPLICATION OF ADVANCED METHODS
  • W6 : GENERATING REAL-WORLD EVIDENCE FOR REAL-WORLD DECISIONS: APPLICATION OF ADVANCED METHODS
  • W6 : GENERATING REAL-WORLD EVIDENCE FOR REAL-WORLD DECISIONS: APPLICATION OF ADVANCED METHODS

    Presentation

    Richard Grieve
    PhD, Professor of Health Economics Methodology, London School of Hygiene and Tropical Medicine, London, UK
  • W7 : VALUE OF INFORMATION (VOI) ANALYSIS FOR RESEARCH DECISIONS: EMERGING GOOD PRACTICE RECOMMENDATIONS FROM THE ISPOR VOI TASK FORCE

    Presentation

    Claire Rothery
    PhD, Senior Research Fellow in Health Economics, University of York, Centre for Health Economics, York, UK
    Hendrik Koffijberg
    PhD, Associate Professor Health Economics, University of Twente, Health Technology & Services Research, Enschede, The Netherlands
    Saskia Knies
    PhD, Policy Advisor Health Economics, National Health Care Institute (ZiN), Diemen, The Netherlands
    Elisabeth Fenwick
    PhD, Director, ICON Clinical Research, Health Economics, Oxford, UK
  • W8 : MODELING SEPARATE LINES OF TREATMENT VERSUS TREATMENT SEQUENCES IN CANCER

    Presentation

    Sonja Sorensen
    MPH, Senior Director, Senior Research Leader, Evidera, Modeling & Simulation, Bethesda, USA
    Matthew Stevenson
    PhD, Professor of Health Technology Assessment, University of Sheffield, School of Health and Related Research, Sheffield, UK

ISPOR FORUMS

  • F10 : THE BURDEN OF COPD IN CENTRAL & EASTERN EUROPE

    Presentation

    Tamas Agh
    MD, PhD, Principal Researcher, Syreon Research Institute, Budapest, Hungary
  • F10 : THE BURDEN OF COPD IN CENTRAL & EASTERN EUROPE

    Presentation

    Konstantin Tachkov
    PhD(c), PhD student, Medical University of Sofia, Sofia, Bulgaria
  • F10 : THE BURDEN OF COPD IN CENTRAL & EASTERN EUROPE

    Presentation

    Maria Kamusheva
    PhD, Assistant Professor, Medical University of Sofia, Faculty of Pharmacy, Sofia, Bulgaria
  • F10 : THE BURDEN OF COPD IN CENTRAL & EASTERN EUROPE

    Presentation

    Josip Culig
    MD, PhD, President, ISPOR Croatia Chapter and Professor, Pharmacology & Clinical Pharmacology & Head, Public Health Institute Zagreb, Pharmacoepidemiology Department, Zagreb, Croatia
  • F2 : METHODS AND PRELIMINARY RESULTS OF THE ISPOR ONCOLOGY HEALTH ECONOMIC MODELING SPECIAL INTEREST GROUP

    Presentation

    Noemi Muszbek
    MSc, Senior Research Scientist, Evidera, London, UK
    Hena Qureshi
    BSc BA, Student, University of Calgary, Community Health Sciences, Calgary, Canada
    Agnes Benedict
    MSc, Executive Director, Evidera, Budapest, Hungary
    Nermeen Nabil Ashoush
    PhD, Lecturer in Clinical Pharmacy and Pharmacy Practice Department, Faculty of Pharmacy, The British University in Egypt, Cairo, Egypt
  • F3 : RARE DISEASE RESEARCH, HTA AND EVIDENCE FOR REIMBURSEMENT

    Presentation

    Ken Redekop
    PhD, Associate Professor, Erasmus University Rotterdam, Rotterdam, The Netherlands
    Sheela Upadhyaha
    BSc, Associate Director Highly Specialised Technologies, National Institute for Health and Care Excellence, Centre for Health Technology Evaluation, London, UK
    Christopher M. Blanchette
    PhD, MBA, Associate Dean, Research & Public Engagement, University of North Carolina at Charlotte, Charlotte, USA
    Sandra Nestler-Parr
    PhD, MSc, MBA, Head of Rare Diseases, Roboleo & Co, Leamington Spa, UK
    Janis Clayton
    BSc, VP and General Manager UK & Ireland, PTC Therapeutics Ltd., Dublin, Ireland
  • F4 : COULD MULTI-STAKEHOLDER PARTNERSHIP IMPROVE PATIENT ACCESS TO BETTER HEALTHCARE IN LATIN AMERICA?
  • F4 : COULD MULTI-STAKEHOLDER PARTNERSHIP IMPROVE PATIENT ACCESS TO BETTER HEALTHCARE IN LATIN AMERICA?

    Presentation

    Diego Rosselli
    MD, MEd, MSc, Associate professor, Pontificia Universidad Javeriana, Clinical Epidemiology and Biostatistics Department, Bogota, Colombia
  • F4 : COULD MULTI-STAKEHOLDER PARTNERSHIP IMPROVE PATIENT ACCESS TO BETTER HEALTHCARE IN LATIN AMERICA?

    Presentation

    Diego F Guarin
    MD, MPH, MA, Senior Director, HEOR & HTA Strategy, Merck-Serono, HEOR & HTA, Latin America, Billerica, USA
  • F4 : COULD MULTI-STAKEHOLDER PARTNERSHIP IMPROVE PATIENT ACCESS TO BETTER HEALTHCARE IN LATIN AMERICA?

    Presentation

    Federico Augustovski
    MD, MSc, PhD, Director, Institute for Clinical Effectiveness and Health Policy (IECS), Health Techonology Assessment and Health Economic Department, Buenos Aires, Argentina
  • F4 : COULD MULTI-STAKEHOLDER PARTNERSHIP IMPROVE PATIENT ACCESS TO BETTER HEALTHCARE IN LATIN AMERICA?
  • F5 : RARE DISEASES MCDA CRITERIA IMPLEMENTATION RESULTS IN EUROPEAN COUNTRIES

    Presentation

    John Yfantopoulos
    PhD, President, ISPOR Greece Chapter and Professor of Health Economics, University of Athens, School of Economics and Political Science, Athens, Greece
  • F5 : RARE DISEASES MCDA CRITERIA IMPLEMENTATION RESULTS IN EUROPEAN COUNTRIES

    Presentation

    Olha Zaliska
    PhD, DSci (Pharm), President, ISPOR Ukraine Chapter and Professor, Danylo Halytsky Lviv National Medical University, Lviv, Ukraine
  • F6 : THE ESTABLISHMENT OF NEGOTIATION COMMITTEE, THERAPEUTIC GUIDELINES AND HEALTH TECHNOLOGY ASSESSMENT EFFORTS IN CEE COUNTRIES
  • F6 : THE ESTABLISHMENT OF NEGOTIATION COMMITTEE, THERAPEUTIC GUIDELINES AND HEALTH TECHNOLOGY ASSESSMENT EFFORTS IN CEE COUNTRIES

    Presentation

    Dragana Atanasijevic
    MD, MSc, President, ISPOR Serbia Chapter, and Consultant, HTA & Healthcare Quality Improvement, Belgrade, Serbia
  • F6 : THE ESTABLISHMENT OF NEGOTIATION COMMITTEE, THERAPEUTIC GUIDELINES AND HEALTH TECHNOLOGY ASSESSMENT EFFORTS IN CEE COUNTRIES

    Presentation

    Mary Geitona
    MD, Professor, University of Peloponnese, Athens, Greece
  • F6 : THE ESTABLISHMENT OF NEGOTIATION COMMITTEE, THERAPEUTIC GUIDELINES AND HEALTH TECHNOLOGY ASSESSMENT EFFORTS IN CEE COUNTRIES

    Presentation

    Joanna Lis
    MSc, MBA, PhD, Director, Sanofi-Aventis, Market Access, Warsaw, Poland
  • F9 : LATE STAGE ONCOLOGY MCDA CRITERIA IMPLEMENTATION RESULTS IN EUROPEAN COUNTRIES

    Presentation

    Bertalan Nemeth
    MSc, Senior Health Economist, Syreon Research Institute, Budapest, Hungary
  • F9 : LATE STAGE ONCOLOGY MCDA CRITERIA IMPLEMENTATION RESULTS IN EUROPEAN COUNTRIES

    Presentation

    Aleksandra Zawodnik
    MSc Pharm, PhD Candidate, Medical University of Warsaw, Department of Experimental and Clinical Pharmacology, Warsaw, Poland
  • F9 : LATE STAGE ONCOLOGY MCDA CRITERIA IMPLEMENTATION RESULTS IN EUROPEAN COUNTRIES

    Presentation

    Oresta Piniazhko
    MSPharm, PhD student, Danylo Halytsky Lviv National Medical University, Lviv, Ukraine